# Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

> **NCT04405401** · PHASE2 · RECRUITING · sponsor: **Centre hospitalier de l'Université de Montréal (CHUM)** · enrollment: 68 (estimated)

## Conditions studied

- Lung Cancer Metastatic

## Interventions

- **RADIATION:** SABR
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04405401
- **Lead sponsor:** Centre hospitalier de l'Université de Montréal (CHUM)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-05
- **Primary completion:** 2025-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405401, "Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04405401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*